The Rise of ‘Computational Social Listening’: How AI is Uncovering Hidden Drug Side Effects For decades, identifying drug side effects relied heavily on clinical trials and post-market reporting. Now, a new approach is gaining traction: analyzing the vast ocean of patient experiences shared on social media. Researchers at the University of Pennsylvania have pioneered a … Read more
Ecuador’s Bold Move Towards Rabies Elimination: A Blueprint for Global Health Security Ecuador is making significant strides towards becoming only the second country in Latin America to eliminate dog-mediated rabies, following Mexico’s lead. This ambitious goal, guided by the Pan American Health Organization (PAHO), centers on mass dog vaccination, robust epidemiological surveillance, and accessible post-exposure … Read more
The Shifting Landscape of Pharmacy Benefit Managers: Accountability and Transparency on the Horizon For years, concerns have mounted regarding the role of pharmacy benefit managers (PBMs) in the prescription drug supply chain. Accusations of prioritizing profits over patient access and affordability have been widespread. Now, a confluence of Congressional action and Department of Labor (DOL) … Read more
AI Revolutionizes Drug Discovery: Lilly’s $2.75 Billion Bet on Insilico The pharmaceutical industry is undergoing a seismic shift, driven by the rapid advancements in artificial intelligence. This week, Eli Lilly took a massive leap forward, announcing a $2.75 billion deal with Hong Kong-based Insilico Medicine to accelerate the development of AI-discovered drugs. This collaboration isn’t … Read more
Averna Therapeutics Bolsters Leadership: What It Signals for the Future of Gene Therapy Averna Therapeutics’ recent appointments of Robert Mabry as Chief Scientific Officer (CSO) and Richard Morris as Chief Financial Officer (CFO) aren’t just internal shifts; they represent a strategic move within the rapidly evolving landscape of genomic medicine. These hires, announced on March … Read more
Trump Administration Pushes for Legislative Drug Pricing Reform Washington D.C. – The White House is actively working to translate its voluntary drug pricing agreements with pharmaceutical companies into formal legislation. Officials are currently sharing draft legislative text with over a dozen major pharmaceutical companies, signaling a continued commitment to lowering prescription drug costs. Building on … Read more
Inovio Pharmaceuticals Investors Face Deadline in Securities Class Action Investors who purchased Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023, and December 26, 2025, may be eligible to participate in a securities class action lawsuit. A lead plaintiff deadline of April 7, 2026, has been set for those wishing to seize a leadership … Read more
AstraZeneca’s COPD Breakthrough: A New Dawn for Lung Disease Treatment? AstraZeneca’s stock surged nearly 5% today following the announcement of positive Phase III trial results for tozorakimab, a novel treatment for Chronic Obstructive Pulmonary Disease (COPD). The drug significantly reduced flare-ups in both former and current smokers, marking a potential turning point in the fight … Read more
Pharmaceutical Kickbacks: A Quarter-Century of Penalties and What’s Next For decades, the pharmaceutical industry has faced scrutiny over practices designed to influence prescribing habits. A recent analysis reveals that, between 2000 and 2025, 64 cases resulted in settlements with the U.S. Government due to alleged kickbacks to physicians. These kickbacks aimed to boost medicine sales … Read more
Tennessee Bill Sparks National Debate Over Pharmacy Benefit Managers A bill currently moving through the Tennessee legislature is igniting a national conversation about the role of pharmacy benefit managers (PBMs) and the future of the pharmaceutical industry. The proposed legislation, Senate Bill 2040, could dramatically reshape how prescription drugs are managed in the state and … Read more